Eurofins-Cerep SA
PAR:ALECR
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
N/A
N/A
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ALECR stock under the Base Case scenario is 20 953.32 EUR. Compared to the current market price of 22 200 EUR, Eurofins-Cerep SA is Overvalued by 6%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Eurofins-Cerep SA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ALECR cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Eurofins-Cerep SA
Balance Sheet Decomposition
Eurofins-Cerep SA
Current Assets | 61m |
Cash & Short-Term Investments | 9.3m |
Receivables | 46.8m |
Other Current Assets | 4.9m |
Non-Current Assets | 11.7m |
Long-Term Investments | 17k |
PP&E | 9.2m |
Intangibles | 2.2m |
Other Non-Current Assets | 237k |
Current Liabilities | 11m |
Accounts Payable | 4.5m |
Accrued Liabilities | 3.5m |
Other Current Liabilities | 3m |
Non-Current Liabilities | 1.5m |
Other Non-Current Liabilities | 1.5m |
Earnings Waterfall
Eurofins-Cerep SA
Revenue
|
46.2m
EUR
|
Cost of Revenue
|
-6.7m
EUR
|
Gross Profit
|
39.5m
EUR
|
Operating Expenses
|
-31.3m
EUR
|
Operating Income
|
8.2m
EUR
|
Other Expenses
|
973k
EUR
|
Net Income
|
9.2m
EUR
|
Free Cash Flow Analysis
Eurofins-Cerep SA
EUR | |
Free Cash Flow | EUR |
ALECR Profitability Score
Profitability Due Diligence
Eurofins-Cerep SA's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
Score
Eurofins-Cerep SA's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
ALECR Solvency Score
Solvency Due Diligence
Eurofins-Cerep SA's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Eurofins-Cerep SA's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALECR Price Targets Summary
Eurofins-Cerep SA
Dividends
Current shareholder yield for ALECR is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Eurofins-Cerep SA engages in providing preclinical drug research services. The company is headquartered in Celle-Levescault, Nouvelle-Aquitaine and currently employs 211 full-time employees. The company went IPO on 2010-03-19. The Company, using its BioPrint technology systems that analyzes pharmaceutical drugs on the market, those that have been withdrawn, and those that failed in the development stages, builds up predictive models of the potential of new drugs. These predictions are based on the drugs' chemical structure and their performance in vitro. The firm then offers solutions to the pharmaceutical and biotechnology sectors on reducing time and costs in the early stages of the drug development process. Clients can also gain access to some of the Company's technology by subscribing to BioPrint. In December 2013, it sold Cerep Inc, its American subsidiary, to Eurofins-Panlabs Inc, part of the Eurofins Scientific SE group.
Contact
IPO
Employees
Officers
The intrinsic value of one ALECR stock under the Base Case scenario is 20 953.32 EUR.
Compared to the current market price of 22 200 EUR, Eurofins-Cerep SA is Overvalued by 6%.